Walleye Capital
IMVT icon

Walleye Capital’s Immunovant IMVT Stock Holding History

Walleye Capital’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$135K Buy
+4,000
New +$158K ﹤0.01% 5047
2026
Q1 		– Sell
-8,600
Closed -$219K – 4662
2025
Q4 		$219K Buy
+8,600
New +$192K ﹤0.01% 3498
2024
Q2 		– Sell
-7,300
Closed -$236K – 5783
2024
Q1 		$236K Sell
7,300
-5,500
-43% -$201K ﹤0.01% 3861
2023
Q4 		$539K Buy
12,800
+12,700
+12,700% +$467K ﹤0.01% 2894
2023
Q3 		$3.84K Buy
+100
New +$2.26K ﹤0.01% 4634

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Walleye Capital's IMVT Position: Q3 2026 in Review

Walleye Capital increased its Immunovant (IMVT) stake by 571% in Q3 2026, buying an estimated $1.49M and bringing the position to 44,490 shares worth $1.5M. The position accounts for ﹤0.01% of the portfolio, ranked #3087.

Walleye Capital first reported a position in IMVT in Q1 2021 and has held it in 13 quarters since. The position peaked at $9.48M in Q4 2022. 160 funds tracked by Wall St. Rank hold IMVT as of Q3 2026.

  • Walleye Capital held 44,490 shares of Immunovant worth $1.5M as of Q3 2026.
  • Walleye Capital bought 37,857 Immunovant shares in Q3 2026, an estimated $1.49M.
  • Immunovant made up ﹤0.01% of Walleye Capital's portfolio in Q3 2026, its #3087 holding.
  • Walleye Capital first reported a position in Immunovant in Q1 2021 and has held it in 13 quarters since.
  • Walleye Capital's Immunovant position peaked at $9.48M in Q4 2022.
  • 160 funds tracked by Wall St. Rank held Immunovant as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.